Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany

In this episode, listen to Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss in German key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany.
person default
Georgios Gakis, MD
person default
Mario Wolfgang Kramer, MD, PhD
Released: May 13, 2021

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:

  • Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
  • Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
  • When to consider first-line treatment with immune checkpoint inhibitor monotherapy
  • Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy

Presenters:

Georgios Gakis, MD  
Professor of Urology, Staff Urologist
University Hospital of Würzburg  
Würzburg, Germany

Mario Wolfgang Kramer, MD, PhD  
Consultant Urologist
Vice Director, Urology
University Hospital Schlewig-Holstein Campus Lübeck
Lübeck, Germany

Acknowledgements

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

Use this web-based tool to see recommendations from 5 experts on treating patients with bladder cancer.

Matthew Galsky, MD person default Shilpa Gupta, MD Matthew I. Milowsky, MD Elizabeth R. Plimack, MD, MS person default Arlene O. Siefker-Radtke, MD Released: July 19, 2021

On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022

Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: July 2, 2021

Downloadable PDF with highlights from a CCO podcast on PARP inhibitors and emerging combination strategies in prostate cancer.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue